Regional overviews

celebrating 20 years Australasia

STATISTICS  
Number of products launched: 3 (2017: 4)#
IMS value of pipeline as at 30 June 2018 anticipated to be launched in:  
0 – 2 years USD113 million
3 – 5 years USD11 million
Number of product recalls: 0 (2017: 3)
Average staff turnover: 13,0% (2017: 7,5%)
Number of work-related fatalities: 0 (2017: 0)
Number of permanent employees:  
Number of permanent employees:  

# The number of product launches has been restated as a result of the refinement of the product launch definition.

 

We supply a diversified portfolio of branded prescription, OTC, consumer and infant nutritional products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semi-solids.

KEY COUNTRIES

Australia, New Zealand

Contribution to Group revenue

Revenue - R'million 2018 2017 (CER) % change
Commercial Pharmaceuticals 4 816 4 658 3
Regional Brands 3 605 3 545 2
Anaesthetics 713 621 15
Thrombosis 21 25 (16)
High Potency & Cytotoxics 477 467 2
Nutritionals 715 772 (7)
Manufacturing – FDP 464 458 1
Total 5 995 5 888 2

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture

 
  • The Australian pharmaceutical sector was valued at AUD17,7 billion as at 30 June 2018 with flat volume growth.
  • Aspen was ranked 3rd by volume and 9th by value in the Australian pharmaceutical sector for the year ended 30 June 2018.
  • Almost one in seven scripts written in Australia is for a product distributed by Aspen.
Source: June 2018 IMS